AGEN
- Agenus Inc.
()
Overview
Company Summary
Agenus Inc. is a biotechnology company that focuses on the development and commercialization of immunotherapies and next-generation vaccines to treat cancer and other diseases. They specialize in the discovery and development of antibody-based therapies, along with adoptive cell therapies and other novel immunotherapies.
The company's primary goal is to leverage the power of the immune system to combat cancer by targeting specific antigens present on tumor cells. Agenus utilizes a proprietary discovery platform called Retrocyte Display�, which enables the identification and optimization of antibodies with enhanced therapeutic potential.
Agenus has built a diverse and robust pipeline of product candidates, which includes both their proprietary programs and partnered programs with other biopharmaceutical and academic institutions. Their product portfolio spans various stages of development, from preclinical to advanced clinical stages.
In addition to their focus on cancer immunotherapy, Agenus is also actively engaged in developing vaccines for infectious diseases. They have developed multiple proprietary vaccine platforms, such as QS-21 Stimulon� adjuvant, to enhance the effectiveness of vaccines targeting conditions like shingles, malaria, and others.
Agenus collaborates with leading academic institutions, biopharmaceutical companies, and governmental organizations to advance their research and development programs. They often enter into licensing and strategic partnerships to facilitate the commercialization of their products and technologies.
Overall, Agenus Inc. is a biotechnology company committed to advancing immunotherapies and vaccines to improve the treatment outcomes for cancer patients and other individuals suffering from infectious diseases.